Look behind the lecture: paying for innovative therapies – why existing methods may not suffice

Written by Brian Godman (Strathclyde Institute of Pharmacy and Biomedical Sciences)
Decision science Health economics ISPOR Look behind the lecture Rare diseases and orphan drugs

In this feature, following his participation in a workshop at the International Society for Pharmacoeconomics and Outcomes Research’s 2020 Asia Pacific meeting (Virtual ISPOR Asia Pacific 2020; 14–16 September), Brian Godman (Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK) discusses current methods used to reimburse and evaluate the cost–effectiveness of therapies, as well as challenges associated with applying these in the context of innovative therapies for rare diseases. Please could you introduce yourself and your organization(s)? I am a Professor working across countries seeking to enhance the quality and efficiency of prescribing, including prescribing of new medicines. Currently, I...

To view this content, please register now for access

It's completely free